Amgen Inc (AMGN) – Pharmaceuticals & Healthcare – market growing at a healthy rate.

 

HTF Market Intelligence released a new research report of 134 pages on title ‘Amgen Inc (AMGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile’  with detailed analysis, forecast and strategies.

Summary

Amgen Inc (Amgen) is a biotechnology company. It undertakes the discovery, development, manufacture and commercialization of innovative human therapeutics. The company products are used in the treatment of cancer, rheumatoid arthritis, kidney disease, bone disease and many other serious illnesses. Amgen’s R&D organization has expertise in multiple treatment modalities, antibodies, large-molecule proteins and small molecules. The company’s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidney disease and in cancer; and Prolia (denosumab) used in the treatment of osteoporosis in postmenopausal women among others. The company has research and development (R&D) facilities in the US, Canada, the UK, Germany and Iceland. Amgen is headquartered in Thousand Oaks, California, the US.

Request a sample report @ https://www.htfmarketreport.com/sample-report/238358-amgen-inc-2

Amgen Inc (AMGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

 

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

 

Scope

 

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

– Business Description – A brief description of the company’s operations.

– Key Employees – A list of the key executives of the company.

– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.

– Key Competitors – A list of the key competitors of the company.

– Key Recent Developments – A brief on recent news about the company.

 

Reasons to Buy

 

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements

– The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

 

Understand the company’s business segments’ expansion / divestiture strategy

– The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

 

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company

– Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

 

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

– The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

 

Stay up-to-date on the major developments affecting the company

– Recent developments concerning the company presented in the profile help you track important events.

 

Gain key insights into the company for academic or business research

– Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

 

Note*: Some sections may be missing if data is unavailable for the company.

Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/238358-amgen-inc-2

 

Table of Contents 

Table of Contents  2

List of Tables  5

List of Figures  8

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017  9

Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017  10

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017  11

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017  12

Amgen Inc, Medical Devices Deals, 2011 to YTD 2017  14

Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017  15

Amgen Inc, Pharmaceuticals & Healthcare, Deal Details  21

Asset Purchase  21

Amgen Acquired Right to BI 836909 from Boehringer Ingelheim  21

Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD479 Million  22

Amgen Completes Acquisition Of Dublin Sterile Plant From Pfizer  23

Amgen Reacquires Rights Of Its Products From Hypermarcas  24

Venture Financing  25

SiteOne Therapeutics Raises USD15 Million in Series B Financing  25

Dezima Pharma Raises US$13 Million In Series A Financing  27

Dezima Pharma Raises Funds Through Seed Financing  28

Gamida Cell Raises US$10 Million In Series E Financing  28

Partnerships  30

Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen  30

SiteOne Therapeutics Enters into R&D Agreement with Amgen  31

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma  32

Nuevolution Enters into Research Agreement with Amgen  33

Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen  33

Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia  34

Amgen Enters into Partnership with Advaxis  35

Amgen Enters into Agreement with Allergan  36

Amgen and Daiichi Sankyo Enter into Agreement  37

Flatiron Health Partners with Amgen  38

Amgen and Merck Enter into Agreement  39

Amgen Enters into Co-Development Agreement with Novartis  39

Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen  40

Amgen Enters into Research Agreement with MD Anderson  41

Innovative Targeting Solutions Enters into Research Agreement with Amgen  42

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery  43

Amgen Forms Joint Venture With Zhejiang Beta Pharma  44

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil  45

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies  46

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement  47

Amgen And Astellas Pharma Announce Joint Venture For Japan  48

Amgen Enters Into Co-Development Agreement With Astellas  49

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test  51

PeptiDream Expands Drug Discovery Agreement with Amgen  51

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs  52

Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics  53

Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research  54

Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies  55

Dako Enters Into Co-Deve

 

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/238358-amgen-inc-2

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=238358

 

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

sales@htfmarketreport.com

Ph: +1 (206) 317 1218

Designed by CyFocus.com
Powered by CyFocus.net